TotalEnergies SE: Information Concerning the Total Number of Voting Rights and Shares in the Share Capital as at June 30, 2025
PARIS, July 04, 2025--(BUSINESS WIRE)--Regulatory News:
TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE):
Date
Total number of shares
Number of voting rights
Theoretical (1)
Exercisable (2)
June 30, 2025
2,281,206,254
2,281,206,254
2,203,252,281
(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting rights have been suspended.
(2) Total number of exercisable voting rights, after deduction of 77,953,973 treasury shares.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250704861784/en/
Contacts
TotalEnergies SE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
LVMH Acquires French Media Group Bey Médias
NEWSMAKER: LVMH Moët Hennessy Louis Vuitton is continuing to expand its media footprint with the acquisition of French media group Bey Médias. Financial details of the deal were not disclosed. More from WWD Moynat Opens Avenue Montaigne Boutique Jonathan Anderson's Dior Debut Draws Daniel Craig, Robert Pattinson, TXT and Rihanna Jonathan Anderson on Building His Dior World, One Show at a Time The luxury group was already a minority shareholder of the company, which publishes daily newspaper L'Opinion and financial news website L'Agefi. It has bought the stakes of founder Nicolas Beytout as well as those of other shareholders including Théthys, which is owned by L'Oréal's Bettencourt founding family; American businessman Ken Fisher, and Dow Jones, the group owned by media titan Rupert Murdoch. According to sources with knowledge of the matter, the acquisition was done through the group's Ufipar subsidiary. L'Opinion and L'Agefi will be in an entity distinct from the Les Échos – Le Parisien group. It is understood that the publications' editorial structures and teams would remain in place. Beytout will continue to serve as the media group's president as well as president and publishing director of L'Opinion, with Rémi Godeau remaining as editor in chief. Meanwhile, Alexandre Garabedian is staying as editorial director of L'Agefi. L'Opinion and parent company Bey Médias were created in 2013 by Beytout, former president of Les Echos – purchased by LVMH in 2007 – and former editorial director of Le Figaro. At the time, they received financing from the French luxury group to launch. Known for its liberal and pro-European stance, it has a partnership with Dow Jones-owned Wall Street Journal, allowing it to translate and publish articles drawn from the American publication. In 2019, Bey Médias acquired L'Agefi, a 114-year-old publication then owned by Artémis, the Pinault family's holding company. Last year, the media group entered unsuccessful negotiations with Czech billionaire businessman Daniel Kretinsky. Prior to that, it was in talks with French-Lebanese global transport tycoon Rodolphe Saadé, who owns several media including business news site La Tribune and TV channel BFMTV. LVMH also owns French people magazine Paris Match, acquired in October, and has owned daily newspaper Le Parisien and its national counterpart, Aujourd'hui en France, since 2015. Best of WWD EXCLUSIVE: Sean Combs Regains Control of Sean John Brand Isabel Marant Said in Play Again: Sources Holding Industriale Invests in Shoe Specialist Valmor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
KFC to open 50 new stores across UK in 2025
Fast food giant KFC has unveiled plans to establish more than 50 new dining locations across the UK in 2025, forming a key part of a £1.5bn ($2.04bn) investment to expand its presence in the UK and Ireland (UK&I). Currently operating 1,000 restaurants nationwide, KFC has set a target to open 500 additional venues by 2034. BDC Magazine reports that the restaurant company has pledged £466m up to 2030 to drive this expansion, while also committing to revamp more than 200 existing sites to upgrade facilities and improve customer satisfaction. To achieve this growth, KFC is searching for both freehold and leasehold properties, focusing on sites in retail parks, leisure complexes, high streets, transport hubs, shopping centres and food courts. The chain is particularly interested in drive-through locations ranging from 0.3 to 1.5 acres and in-line units spanning between 1,200ft² and 2,500ft². The expansion will cover all regions of the UK and Ireland, with a strong emphasis on accessibility and prominence. To encourage property experts to identify suitable locations, KFC is offering a £20,000 finder's fee for successful site recommendations. The initiative highlights KFC's confidence in the UK and Irish markets and its dedication to long-term development. In November 2023, KFC UK&I collaborated with Uber Direct to facilitate fast order deliveries to its customers in the region. Orders placed by the customers via the KFC app will use the same tech and courier network that powers Uber Eats. "KFC to open 50 new stores across UK in 2025" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 hours ago
- Yahoo
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Novo Nordisk A/S' (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy. As rival Eli Lilly and Co.'s (NYSE:LLY) Zepbound gains momentum, the Danish pharmaceutical giant is grappling with the fallout of those early decisions. Wegovy, approved in the U.S. in mid-2021, marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then. Trending: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — But the company has struggled to keep pace with Lilly's Zepbound, which has surpassed Wegovy in weekly new prescriptions this year. Amid concerns over its competitiveness in the weight-loss market, Novo is undergoing a leadership shake-up, including the recent dismissal of CEO Lars Fruergaard Jorgensen and earlier departures like U.S. chief Doug Langa. Sources told Reuters that during tense internal meetings, sales and marketing staff warned Langa about launching Wegovy too quickly after FDA approval. They urged a delay until supply and insurance coverage were more secure. With a list price of up to $1,300 per month, many patients found the drug unaffordable without insurance, and Novo missed an opportunity to build a more stable launch pad while Lilly's market entry was still years company leadership in Copenhagen held to conservative sales expectations through 2025, Reuters report highlighted, underestimating the scale of demand driven by the global obesity epidemic. Former employees said Novo had internal indicators pointing to stronger uptake but failed to adjust its strategy accordingly. The consequences were swift. Wegovy's launch was plagued by supply shortages, leaving patients without doses and discouraging new users. The high cost also pushed some patients toward the gray market of compounded drugs. Novo further faced criticism for pricing Wegovy significantly higher than its diabetes drug Ozempic, while Lilly entered the market with Zepbound at $1,080 and provided steep discounts through its LillyDirect pharmacy. One former insider claimed that Novo hesitated to offer competitive rebates to pharmacy benefit managers (PBMs), limiting the drug's accessibility. This reluctance hurt relationships with insurers and failed to secure broader coverage, placing Novo at a disadvantage compared to Lilly's aggressive pricing and reimbursement strategies. Recently, Novo Nordisk launched its weight-loss drug Wegovy (semaglutide) in India to compete with Eli Lilly. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo by Tobias Arhelger via Shutterstock This article Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
